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Objectives The aim of this study was to assess the impact of extreme (class III) obesity (body mass index [BMI]
40 kg/m2) on care and outcomes in patients with ST-segment elevation myocardial infarction (STEMI).
Background Although its prevalence is increasing rapidly, little is known about the impact of extreme obesity on STEMI pre-
sentation, treatments, complication rates, and outcomes.
Methods The relationship between BMI and baseline characteristics, treatment patterns, and risk-adjusted in-hospital out-
comes was quantified for 50,149 patients with STEMI from the National Cardiovascular Data Registry (NCDR)
ACTION Registry–GWTG.
Results The proportions of patients with STEMI by BMI category were as follows: underweight (BMI 18.5 kg/m2) 1.6%,
normal weight (18.5 kg/m2 BMI 25 kg/m2) 23.5%, overweight (25 kg/m2 BMI 30 kg/m2) 38.7%, class I
obese (30 kg/m2 BMI 35 kg/m2) 22.4%, class II obese (35 kg/m2 BMI 40 kg/m2) 8.7%, and class III
obese 5.1%. Extreme obesity was associated with younger age at STEMI presentation (median age 55 years for
class III obese vs. 66 years for normal weight); a higher prevalence of diabetes, hypertension, and dyslipidemia;
a lower prevalence of smoking; and less extensive coronary artery disease and higher left ventricular ejection
fraction. Process-of-care measures were similar across BMI categories, including the extremely obese. Using
class I obesity as the referent, risk-adjusted in-hospital mortality rates were significantly higher only for class III
obese patients (adjusted odds ratio: 1.64; 95% confidence interval: 1.32 to 2.03).
Conclusions Patients with extreme obesity present with STEMI at younger ages and have less extensive coronary artery dis-
ease, better left ventricular systolic function, and similar processes and quality of care. Despite these advan-
tages, extreme obesity remains independently associated with higher in-hospital mortality. (J Am Coll Cardiol
2011;58:2642–50) © 2011 by the American College of Cardiology Foundation
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December 13/20, 2011:2642–50 Extreme Obesity and STEMIThe prevalence of obesity, defined according to National
Heart, Lung, and Blood Institute criteria (1) as a body mass
index (BMI) 30 kg/m2, has more than doubled over the
ast 3 decades (2) and currently affects 1 in 3 U.S. adults (3).
besity is strongly associated with cardiovascular risk fac-
ors such as diabetes, hypertension, and dyslipidemia. In
ddition, obese patients have an increased burden of coro-
ary artery disease and a higher incidence of acute coronary
yndromes (4–6). Despite the adverse association between
besity and incident cardiovascular disease, a paradoxical
urvival benefit after myocardial infarction (MI) has been
ttributed to obesity (7–13). Prior studies, however, have
ncluded relatively few subjects with extreme obesity (class
II, BMI 40 kg/m2). The relationships between obesity
nd non–ST-segment elevation myocardial infarction
NSTEMI) presentation, processes of care, and outcomes
ave been described previously (14). However, little is
nown about the relationship between obesity, particularly
xtreme obesity, and care and outcomes in ST-segment
levation MI (STEMI).
See page 2651
Patient demographics, presentation, and treatments differ
notably between STEMI and NSTEMI populations. It is
possible that extreme obesity may affect logistical issues such
as STEMI diagnosis, cardiac catheterization laboratory
table weight limits, problems with vascular access, and
appropriate dosing of anticoagulant therapies. In addition,
higher complication rates from interventional and medical
therapies in obese patients, whether actual or perceived, may
substantively affect risk/benefit calculations and alter man-
agement. To better clarify the impact of extreme obesity on
STEMI care and outcomes, we analyzed the association
between BMI categories and baseline characteristics, treat-
ment, and in-hospital outcomes for 50,149 patients with
STEMI from the National Cardiovascular Data Registry
(NCDR) Acute Coronary Treatment and Intervention
Outcomes Network (ACTION) Registry–Get With The
Guidelines (GWTG) (15–17).
Methods
Data collection. The ACTION Registry–GWTG, cre-
ated by a merger of the American College of Cardiology
Foundation’s NCDR ACTION Registry and the American
Heart Association’s GWTG program, collects and reports
data for patients with STEMI and NSTEMI from 360
participating centers nationwide. Data abstraction was per-
formed retrospectively by trained data collectors via review
of medical records. Demographic and clinical information,
clinical presentation, medical therapies and associated con-
traindications, use and timing of cardiac procedures, labo-
ratory results, and in-hospital outcomes were recorded using
standardized definitions; details of data collection have been
reported previously (15–18). pStudy population. The present
study is based on the 51,980
subjects enrolled in the registry
between January 1, 2007, and
June 30, 2009, who were diag-
nosed with STEMI (defined as
the clinical presentation of acute
MI plus 1 of the following: new
or presumed new ST-segment
elevation, new left bundle branch
block, or isolated posterior MI).
We excluded 1,831 subjects who
did not have BMI data available.
This resulted in a cohort of
50,149 subjects from 344 centers
for the BMI category prevalence
estimates. For analyses of pro-
cesses of care and outcomes, we
further excluded the 820 subjects
in the underweight category, de-
fined by National Heart, Lung, and Blood Institute criteria
as BMI 18.5 kg/m2, because of the small proportion of
subjects in this category (1.6%) and the potential impact of
confounding by comorbid conditions not captured in the
registry, which could prevent proper characterization of the
true relationship between BMI and in-hospital course.
Therefore, all analyses in the present study, except BMI
category prevalence estimates, are based on the 49,329
patients with STEMI and BMI 18.5 kg/m2.
Exposure variable. BMI was calculated on the basis of
height and weight recorded by treating physicians at the
time of STEMI presentation and divided into clinically
relevant categories on the basis of National Heart, Lung,
and Blood Institute criteria (1): underweight (BMI 18.5
kg/m2), normal weight (18.5 kg/m2 BMI 25 kg/m2),
verweight (25 kg/m2 BMI 30 kg/m2), class I obese (30
kg/m2 BMI 35 kg/m2), class II obese (35 kg/m2 BMI
40 kg/m2), and class III obese (BMI 40 kg/m2). The
rimary outcome of the present study was all-cause mortal-
ty. Secondary outcomes included rate and type of reperfu-
ion, time to percutaneous coronary intervention (PCI), and
ates of reinfarction, congestive heart failure (HF), cardio-
enic shock, stroke, major bleeding, and red blood cell
ransfusion unrelated to coronary artery bypass graft surgery,
hich have been defined previously (15–17).
tatistical analysis. Demographics, clinical presentation,
edical therapies, use and timing of cardiac procedures,
aboratory results, and in-hospital outcomes were compared
cross BMI categories. To evaluate the relationship between
n-hospital outcomes and BMI categories, the logistic gen-
ralized estimating equations method with exchangeable
orking correlation matrix was used to account for within-
ospital correlation of responses. Variables used for in-
ospital mortality adjustment were from the validated ACTION
egistry–GWTG in-hospital mortality model (19): age,
Abbreviations
and Acronyms
BMI  body mass index
GWTG  Get With the
Guidelines
HF  heart failure
LV  left ventricular
MI  myocardial infarction
NCDR  National
Cardiovascular Data
Registry
NSTEMI  non–ST-segment
elevation myocardial
infarction
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarctionrior peripheral artery disease, systolic blood pressure on
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Extreme Obesity and STEMI December 13/20, 2011:2642–50presentation, heart rate on presentation, HF or shock on
admission (HF only, shock only or HF with shock, none),
electrocardiographic findings (STEMI, ST-segment changes
vs. no ST-segment changes), initial troponin ratio, and initial
serum creatinine. ST-segment changes included ST-segment
depressions or transient ST-segment elevations, and no ST-
segment changes included T-wave inversions and no electro-
cardiographic changes. Variables used for major bleeding
adjustment were from the validated ACTION Registry–
GWTG in-hospital major bleeding model (17): female sex,
age, diabetes, prior peripheral artery disease, body weight
(excluded from the model for the present study), home
warfarin therapy, heart rate on presentation, systolic blood
pressure on presentation (130, 130 to 160, or 160 mm
Hg), HF on presentation (HF only, shock only or HF with
shock, none), electrocardiographic findings (STEMI, ST-
segment changes vs. no ST-segment changes), initial serum
creatinine, and initial hemoglobin. NSTEMI was dropped
from both models because patients with NSTEMI were
excluded from this analysis. Subjects in the class I obesity
category were used as the referent group for the analyses of
clinical outcomes; this group was selected a priori as the
referent because of the previously well-described “U-shaped”
relationship between BMI and outcomes in patients with a
broad spectrum of existing cardiovascular disease (20) as well as
he results of prior work examining NSTEMI and BMI in the
CTION Registry (14). Adjusted associations were displayed
s odds ratios and 95% confidence intervals. All statistical
nalyses were performed using SAS version 9.2 (SAS Institute
nc., Cary, North Carolina). Values of p 0.05 were consid-
red statistically significant.
esults
he proportions of patients with STEMI by BMI category
ere as follows: underweight 1.6%, normal weight 23.5%,
verweight 38.7%, class I obese 22.4%, class II obese 8.7%,
nd class III obese 5.1%. Class III obese patients with
TEMI were more than a decade younger than their
ormal-weight counterparts (Table 1). Class III obese
atients with STEMI were more likely to be women and of
elf-reported African American race/ethnicity compared
ith all other weight categories. Overall, 29.5% of patients
ere women, compared with 42.6% of the extremely obese
atients. Overall, 7.4% of the cohort was of African Amer-
can race/ethnicity, compared with 11.4% of the class III
bese patients. Taken together, these trends resulted in an
ncrease in the prevalence of African American race/
thnicity from 6.2% of normal-weight women to 15.3% of
lass III obese women. Smoking decreased, while other
raditional cardiac risk factors increased across increasing
ategories of obesity. Class III obese patients were almost
-fold more likely to have diabetes mellitus than their
ormal-weight counterparts. Hemoglobin and low-density
ipoprotein cholesterol were higher while high-density lipo-
rotein was lower for class III obesity compared withormal weight (Table 2). The extent of coronary disease, in
erms of number of vessels affected, and the likelihood of
aving moderate to severe left ventricular (LV) systolic
ysfunction also decreased progressively across increasing
MI categories (Table 2).
Reperfusion was attempted in more than 90% of patients
cross all BMI categories (Table 2). No differences were
resent in the proportion of patients receiving fibrinolytic
herapy or PCI according to BMI, even among those with
xtreme obesity, with 80% of patients in all BMI groups
eceiving primary PCI. In-hospital use of evidence-based
edical therapies was high overall and similar across BMI
roups. Similarly, prescription of evidence-based therapies
t hospital discharge, including aspirin, clopidogrel, beta-
lockers, and angiotensin-converting enzyme inhibitors or
ngiotensin II receptor blockers, was high and did not differ
cross BMI groups, including class III obesity (Table 2).
tatin therapy was slightly less common at discharge among
lass III obese patients. Rates of counseling regarding
moking cessation, dietary modification and exercise, and
eferral to cardiac rehabilitation were similarly high across
MI categories, including class III obesity.
In unadjusted analyses, a U-shaped association with BMI
ategories was seen for both mortality (Fig. 1) and major
leeding (Fig. 2). Rates of adverse outcomes in general were
ighest among normal-weight patients, lower in overweight
nd mild to moderately obese patients, and then increased
gain in patients with class III obesity (Table 3). After
ultivariate adjustment, compared with class I obese pa-
ients, the adjusted odds of death were not significantly
ifferent for normal-weight, overweight, and class II obese
atients. Odds of death were 64% higher for class III obese
atients compared with class I obese patients (Fig. 1). In
ontrast, the adjusted odds of major bleeding were highest
n normal-weight patients and did not differ significantly for
lass III compared with class I obese patients (Fig. 2).
iscussion
n this contemporary analysis of the relationship between
MI and clinical characteristics, treatment patterns, and
n-hospital outcomes for 50,149 patients with STEMI, we
bserved that: 1) three-fourths of patients with STEMI
ere overweight or obese; 2) class III obesity (BMI 40
g/m2) now affects 1 in 20 patients with STEMI and is
particularly common in African American women present-
ing with STEMI (more than 1 in 7); 3) the most obese
patients with STEMI presented more than a decade
younger than their normal-weight counterparts, with less
extensive coronary artery disease and better LV systolic
function despite a higher risk factor burden; 4) processes
and quality-of-care measures did not differ in a clinically
meaningful way for obese patients, including class III obese
patients; and 5) despite similar processes and quality of care
and a lower risk profile, class III obesity was associated with
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December 13/20, 2011:2642–50 Extreme Obesity and STEMIa notable increase in the risk for in-hospital mortality but
not for major bleeding.
Obesity prevalence and presentation characteristics. The
prevalence of obesity in patients presenting with STEMI
was 36.2%, and that of overweight and obesity combined
was 74.9%. The closest comparable national obesity preva-
lence data available, from the NHANES (National Health
and Nutrition Examination Survey) in 2008 (21), show a
lower prevalence of obesity (33.8%) and overweight and
obesity combined (68.0%) in the general population of U.S.
adults age 20 years. The prevalence of class III obesity
Demographics, Medical History, and Home Medications Stratified bTable 1 Demographics, Medical History, and Home Medication
Variable
Normal Weight
(18.5 to <25)
Overweigh
(25 to <3
(n  11,780) (n  19,39
Demographics
BMI (kg/m2) 23.1 (21.7–24.1) 27.4 (26.3–
Age (yrs) 66 (55–78) 60 (52–7
Female 4,446 (37.7%) 4,671 (24.1%
Race/ethnicity
Women (n  14,544)
Caucasian 3,878 (87.7%) 3,962 (85.4%
Black 273 (6.2%) 423 (9.1%)
Asian 92 (2.1%) 46 (1.0%)
Hispanic 104 (2.4%) 142 (3.1%)
Other 73 (1.7%) 68 (1.5%)
Men (n  34,785)
Caucasian 6,034 (82.8%) 12,584 (86.1%
Black 604 (8.3%) 877 (6%)
Asian 221 (3.0%) 215 (1.5%)
Hispanic 270 (3.7%) 618 (4.2%)
Other 162 (2.2%) 317 (2.2%)
Medical history
Current/recent smoker 5,299 (45.0%) 8,355 (43.1%
Hypertension 6,698 (56.9%) 11,343 (58.5%
Dyslipidemia 5,109 (43.4%) 9,647 (49.7%
Diabetes mellitus 1,749 (14.8%) 3,788 (19.5%
Prior MI 2,265 (19.2%) 3,602 (18.6%
Prior PCI 2,140 (18.2%) 3,638 (18.8%
Prior CABG 824 (7.0%) 1,373 (7.1%)
Atrial fibrillation or flutter 254 (5.1%) 287 (3.5%)
Prior stroke 781 (6.6%) 879 (4.5%)
Peripheral artery disease 908 (7.7%) 1,007 (5.2%)
Prior CHF 726 (6.2%) 780 (4.0%)
Home medications
Aspirin 3,877 (32.9%) 6,542 (33.7%
Clopidogrel 1,122 (9.5%) 1,643 (8.5%)
Beta-blockers 3,178 (27.0%) 5,031 (25.9%
ACE inhibitors 2,261 (19.2%) 3,950 (20.4%
Angiotensin receptor blockers 798 (6.8%) 1,430 (7.4%)
Aldosterone-blocking agents 126 (1.1%) 158 (0.8%)
Statins 3,091 (26.2%) 5,658 (29.2%
Values are median (interquartile range) or n (%).
ACE  angiotensin-converting enzyme; BMI  body mass index; CABG  coronary artery bypass
intervention.(BMI 40 kg/m2) in this NHANES cohort was 5.7% bverall, with the prevalence in women (7.2%) higher than in
en (4.2%) and the highest prevalence seen among non-
ispanic black women (14.2%) (21). The higher obesity
revalence among patients with STEMI compared with the
eneral population likely reflects the contribution of obesity
o the pathogenesis of STEMI, which is mediated at least in
art by increases in hypertension, diabetes, and dyslipidemia
n obese individuals. Importantly, in the class III obese
ubgroup, the overrepresentation of African American and
emale patients and the younger age of these patients at
resentation suggest the possibility that class III obesity may
I Categoryatified by BMI Category
BMI Category (kg/m2)
Class I Obese
(30 to <35)
Class II Obese
(35 to <40)
Class III Obese
(>40)
(n  11,234) (n  4,376) (n  2,548)
32.0 (30.9–33.3) 36.9 (35.9–38.1) 43.4 (41.4–47.2)
58 (50–67) 56 (49–65) 55 (48–64)
2,962 (26.4%) 1,371 (31.3%) 1,094 (42.9%)
2,453 (83.7%) 1,123 (82.4%) 876 (80.7%)
327 (11.2%) 173 (12.7%) 166 (15.3%)
26 (0.9%) 5 (0.4%) 1 (0.1%)
69 (2.4%) 39 (2.9%) 26 (2.4%)
56 (1.9%) 23 (1.7%) 17 (1.6%)
7,163 (87.2%) 2,607 (87.3%) 1,256 (86.8%)
508 (6.2%) 195 (6.5%) 125 (8.6%)
53 (0.6%) 17 (0.6%) 5 (0.3%)
347 (4.2%) 115 (3.9%) 46 (3.2%)
143 (1.7%) 51 (1.7%) 15 (1.0%)
4,764 (42.4%) 1,872 (42.8%) 1,051 (41.2%)
7,282 (64.8%) 3,032 (69.3%) 1,881 (73.8%)
6,063 (54.0%) 2,457 (56.1%) 1,427 (56.0%)
3,049 (27.1%) 1,538 (35.1%) 1,110 (43.6%)
2,203 (19.6%) 915 (20.9%) 530 (20.8%)
2,289 (20.4%) 972 (22.2%) 545 (21.4%)
800 (7.1%) 309 (7.1%) 141 (5.5%)
166 (3.4%) 78 (4.2%) 38 (3.2%)
473 (4.2%) 176 (4.0%) 107 (4.2%)
507 (4.5%) 174 (4.0%) 141 (5.5%)
506 (4.5%) 230 (5.3%) 192 (7.5%)
3,882 (34.6%) 1,555 (35.5%) 876 (34.4%)
1,025 (9.1%) 444 (10.1%) 288 (11.3%)
3,151 (28.0%) 1,366 (31.2%) 841 (33.0%)
2,577 (22.9%) 1,140 (26.1%) 706 (27.7%)
1,050 (9.3%) 470 (10.7%) 305 (12.0%)
125 (1.1%) 59 (1.3%) 48 (1.9%)
3,511 (31.3%) 1,466 (33.5%) 879 (34.5%)
urgery; CHF  congestive heart failure; MI  myocardial infarction; PCI  percutaneous coronaryy BMs Str
t
0)
1)
28.7)
1)
)
)
)
)
)
)
)
)
)
)
)
)
)e contributing to premature MI in African American
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Extreme Obesity and STEMI December 13/20, 2011:2642–50Presentation Characteristics, Reperfusion Strategy and Medical Therapy,Discharge Medications, Counseling, and Referrals Stratified by BMI CategoryTable 2 Presentation Charact istics, Reperfusio Strategy and Medical Therapy,Discharge Medications, Counseling, and Referrals Stratified by BMI Category
Variable
BMI Category (kg/m2)
Normal Weight
(18.5 to <25)
Overweight
(25 to <30)
Class I Obese
(30 to <35)
Class II Obese
(35 to <40)
Class III Obese
(>40)
(n  11,780) (n  19,391) (n  11,234) (n  4,376) (n  2,548)
Initial laboratory values
Hemoglobin (g/dl) 13.8 (12.5–15.0) 14.4 (13.2–15.4) 14.5 (13.3–15.6) 14.5 (13.3–15.6) 14.3 (13.1–15.5)
Total cholesterol (mg/dl) 161 (134–190) 168 (141–198) 172 (143–201) 173 (145–203) 171 (145–202)
HDL cholesterol (mg/dl) 39 (32–48) 35 (30–43) 34 (29–41) 33 (28–40) 34 (29–41)
LDL cholesterol (mg/dl) 97 (74–123) 103 (79.0–129.6) 104 (79–130) 104 (79–130) 103 (79–130)
Triglycerides (mg/dl) 97 (68–142) 121 (84–177) 140 (96–208) 148 (101–224) 144 (100–218)
Serum creatinine (mg/dl) 1.1 (0.9–1.2) 1.1 (0.9–1.3) 1.1 (0.9–1.3) 1.1 (0.9–1.2) 1.1 (0.8–1.2)
Presentation characteristics
HF 1,594 (13.5%) 2,127 (11.0%) 1,173 (10.4%) 506 (11.6%) 280 (11.0%)
Shock 839 (7.1%) 1,151 (5.9%) 579 (5.2%) 241 (5.5%) 141 (5.5%)
Heart rate (beats/min) 77 (64–93) 77 (64–91) 79 (66–93) 80 (68–95) 82 (70–96)
SBP (mm Hg) 134 (113–154) 138 (118–159) 141 (120–160) 142 (121–163) 143 (122–164)
eGFR (ml/min/1.73 m2)* 71.5 (56.0–88.1) 72.9 (58.6–88.1) 72.9 (58.9–87.7) 73.7 (58.8–89.7) 74.3 (58.9–91.8)
Number of diseased vessels†
No significant disease 338 (3.2%) 432 (2.4%) 214 (2.0%) 107 (2.6%) 72 (3.1%)
1 3,819 (36.4%) 6,782 (37.6%) 4,113 (39.3%) 1,605 (39.2%) 1,029 (44.1%)
2 3,323 (31.6%) 5,765 (32%) 3,305 (31.6%) 1,339 (32.7%) 699 (30.0%)
3 2,983 (28.4%) 4,978 (27.6%) 2,781 (26.6%) 1,036 (25.3%) 522 (22.4%)
LV ejection fraction (%)‡
50 4,629 (43.1%) 8,645 (48.3%) 5,093 (49.3%) 2,062 (51.3%) 1,171 (51.0%)
40–50 2,789 (26.0%) 4,743 (26.5%) 2,722 (26.3%) 1,019 (25.3%) 632 (27.6%)
25–40 2,476 (23.0%) 3,552 (19.8%) 1,991 (19.3%) 764 (19.0%) 377 (16.4%)
25 751 (7.0%) 839 (4.7%) 447 (4.3%) 146 (3.6%) 86 (3.7%)
Reperfusion strategy§
Overall reperfusion 8,715 (92.3%) 15,475 (93.5%) 9,020 (93.9%) 3,502 (93.5%) 1,978 (93%)
Thrombolytic therapy 1,212 (12.8%) 2,311 (13.9%) 1,356 (14%) 554 (14.7%) 304 (14.1%)
Primary PCI 7,627 (80.8%) 13,398 (80.9%) 7,801 (81.2%) 2,996 (80%) 1,711 (80.4%)
Arrival to primary PCI (min) 69 (53–87) 68 (52–85) 68 (53–86) 69 (54–87) 73 (58–90)
CABG 766 (7.2%) 1,388 (7.7%) 815 (7.8%) 291 (7.1%) 147 (6.3%)
Arrival to CABG (h) 41.0 (68.0–100.1) 38.6 (52.0–90.9) 38.1 (46.0–90.1) 54.9 (69.0–120.5) 45.9 (82.0–132.8)
Medications within 24 h§
Aspirin 11,253 (97.9%) 18,721 (98.5%) 10,880 (98.7%) 4,232 (98.8%) 2,436 (98.1%)
Clopidogrel 9,471 (85.6%) 16,318 (88.7%) 9,487 (89%) 3,687 (88.2%) 2,108 (87.4%)
Beta-blocker 9,263 (94.2%) 16,027 (95.5%) 9,581 (96.1%) 3,747 (95.2%) 2,170 (95.5%)
ACE inhibitors or ARBs 5,347 (50.8%) 9,945 (55.6%) 6,209 (59.6%) 2,435 (59.8%) 1,435 (60.6%)
Aldosterone-blocking agents 228 (2.0%) 327 (1.8%) 208 (1.9%) 85 (2.0%) 57 (2.3%)
Statins 7,407 (66.3%) 12,981 (69.9%) 7,608 (70.5%) 2,928 (69.6%) 1,683 (68.9%)
Glycoprotein IIb/IIIa inhibitors 7,532 (68.9%) 13,495 (73.4%) 8,035 (75.1%) 3,092 (74.0%) 1,737 (71.9%)
Heparin¶
None 1,241 (10.7%) 1,898 (9.9%) 1,128 (10.1%) 417 (9.6%) 253 (10.0%)
Low–molecular weight 1,138 (9.8%) 1,683 (8.8%) 1,014 (9.1%) 435 (10.0%) 218 (8.6%)
Unfractionated 8,316 (71.9%) 14,268 (74.4%) 8,223 (74%) 3,161 (72.9%) 1,859 (73.7%)
Both 822 (7.1%) 1,268 (6.6%) 721 (6.5%) 305 (7.0%) 178 (7.1%)
Bivalirudin¶ 1,581 (13.7%) 2,787 (14.5%) 1,620 (14.6%) 623 (14.4%) 382 (15.1%)
Discharge medications§
Aspirin 9,813 (98.4%) 16,909 (98.6%) 9,865 (98.7%) 3,837 (98.9%) 2,157 (98.2%)
Clopidogrel 8,830 (90.2%) 15,542 (92.1%) 9,105 (92.1%) 3,498 (91.8%) 1,995 (91.9%)
Warfarin 830 (8.1%) 1,267 (7.3%) 725 (7.1%) 285 (7.2%) 147 (6.6%)
Beta-blockers 9,343 (96.5%) 16,372 (97.5%) 9,612 (97.6%) 3,742 (97.9%) 2,113 (97.2%)
ACE inhibitors or ARBs 2,045 (85%) 3,094 (87.7%) 1,788 (88.7%) 645 (88.6%) 336 (89.6%)
Aldosterone-blocking agents 329 (8.2%) 495 (7.4%) 333 (7.5%) 135 (7.1%) 79 (6.6%)
Statins 9,050 (90.8%) 16,011 (93.7%) 9,379 (93.8%) 3,647 (94.2%) 2,033 (91.9%)Continued on next page
ensity l
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that class III obesity was associated with early mortality after
MI and suggests the possibility that increasing rates of class
III obesity in African American women may contribute to
worsening race-based and sex-based disparities in outcomes
after STEMI (22).
Despite a higher prevalence of traditional cardiac risk
factors, obese patients tended to have less extensive coronary
disease and LV systolic dysfunction, likely because they
presented with STEMI at much younger ages than their
normal-weight counterparts; class III obese patients were on
average more than a decade younger than normal-weight
patients. Brain natriuretic peptide and N-terminal pro–
brain natriuretic peptide decreased markedly across increas-
ing BMI categories, disproportionately to underlying differ-
ences in LV function or clinical HF, most likely reflecting
the known inverse relationship between higher body mass
and lower natriuretic peptide concentrations (23).
ContinuedTable 2 Continued
Variable
Normal Weight
(18.5 to <25)
Overwei
(25 to <
(n  11,780) (n  19,3
Discharge interventions§
Smoking cessation counseling 4,639 (96.9%) 7,522 (96
Diet modification counseling 9,567 (93.6%) 16,535 (94
Cardiac rehabilitation referral 7,456 (79.9%) 13,494 (81
Exercise counseling 8,819 (86.9%) 15,331 (88
Values are median (interquartile range) or n (%). *Estimated using the MDRD (Modification of
catheterization. ‡Among patients who had LV ejection fraction measured. §Among eligible patien
ARB angiotensin receptor blocker; eGFR estimated glomerular filtration rate; HDL high-d
abbreviations as in Table 1.
Figure 1 In-Hospital Mortality by BMI
Unadjusted and adjusted odds of in-hospital mortality across body mass index
(BMI) categories, using class I obesity as the referent. After multivariate adjust-
ment, extreme (class III) obesity was associated with increased in-hospital mor-
tality (odds ratio: 1.64; 95% confidence interval: 1.32 to 2.03).Process of care. Contrary to our a priori hypothesis, we
observed few meaningful differences in processes of care for
obese patients, including those with class III obesity. For
the subset undergoing primary PCI, no differences were
noted regarding the administration of reperfusion therapy,
with the exception of a slightly longer door-to-balloon time,
a difference we believe is too small to be clinically mean-
ingful. Moreover, the administration of concomitant anti-
platelet and antithrombotic agents and the initiation of
secondary prevention therapies such as statins and beta-
blockers were similar across BMI categories. Prescription of
guideline-indicated medications at discharge, dietary coun-
seling, referral to cardiac rehabilitation, and counseling
regarding exercise were also similar across weight categories,
with obese patients receiving appropriate referrals as often as
their normal-weight counterparts. These data are encour-
aging and suggest the absence of an obesity-related system-
BMI Category (kg/m2)
Class I Obese
(30 to <35)
Class II Obese
(35 to <40)
Class III Obese
(>40)
(n  11,234) (n  4,376) (n  2,548)
4,316 (97.0%) 1,683 (96.7%) 926 (96.4%)
9,711 (95.2%) 3,765 (95.2%) 2,148 (95.6%)
7,944 (81.9%) 3,112 (82.4%) 1,758 (82.6%)
9,038 (89%) 3,533 (89.8%) 1,961 (87.7%)
Renal Disease) formula. Excludes dialysis patients. †Among patients who underwent cardiac
ludes transfer-in patients. ¶Any time during hospital stay.
ipoprotein; HF heart failure; LDL low-density lipoprotein; SBP systolic blood pressure; other
Figure 2 Major Bleeding by BMI
Unadjusted and adjusted 8 odds of major bleeding across body mass index
(BMI) categories, using class I obesity as the referent. After multivariate adjust-
ment, normal weight was associated with increased major bleeding (odds ratio:
1.18; 95% confidence interval: 1.08 to 1.30), while extreme (class III) obesity
was not (odds ratio: 1.09; 95% confidence interval: 0.94 to 1.26).ght
30)
91)
.8%)
.7%)
.4%)
.1%)
Diet in
ts. Exc
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obese patients.
Obesity and in-hospital mortality. The adjusted odds of
death were lowest for class I obese patients and were not
significantly different for normal-weight, overweight, or
class II obese patients but were significantly higher for class
III compared with class I obese patients. The observed
increase in mortality in the class III obese patients, which
persisted after multivariate adjustment, is of particular
concern given the very rapid rise in class III obesity, far
exceeding the overall increase in obesity prevalence in the
U.S. population. From 1960 to 2004, national estimates of
obesity prevalence as a whole increased from 13.3% (10.7%
in men, 15.8% in women) to 32.9% (31.7% in men, 34.0%
in women), a relative increase of almost 150%. Over the
same time interval, however, the population prevalence of
class III obesity increased from 0.9% (0.3% in men, 1.4% in
women) to 5.1% (3.0% in men, 7.3% in women), a relative
increase of 460% (2).
The mechanism for this increase in mortality risk in class
III obese patients presenting with STEMI is not known, as
these patients are younger, have less extensive coronary
disease, less LV systolic dysfunction, and higher estimated
glomerular filtration rates, and receive similar care compared
with less obese patients. Thus, class III obesity must either
carry intrinsic hazard or must be accompanied by hidden
comorbidities not captured by the registry. Obese patients
have an increased total body blood volume, higher filling
pressures, and increased sympathetic activation, which lead
to increased stroke volume and heart rate; cardiac work is
increased, and this may be accentuated at very elevated levels
of adiposity seen in class III obese patients. Cardiac struc-
tural changes in class III obesity include markedly increased
LV mass (20), known to be a risk factor for increased
ventricular arrhythmias and sudden cardiac death. In addi-
tion, class III obesity has been described as an inflammatory
and prothrombotic state (24), which may also contribute to
adverse prognosis. Although published research does not
reach a consensus on the effect of obesity on in-hospital
In-Hospital Clinical Events Stratified by BMI CategoryTable 3 In-Hospital Clinical Events Stratified by BMI Category
Variable
Normal Weight
(18.5 to <25)
Overweight
(25 to <30)
(n  11,780) (n  19,391)
Death 868 (7.7%) 919 (5.0%)
Recurrent MI 138 (1.2%) 184 (1.0%)
Death or MI 960 (8.5%) 1,058 (5.7%)
Cardiogenic shock 849 (7.5%) 1,106 (6.0%)
Congestive HF 898 (8.0%) 1,099 (5.9%)
Stroke 118 (1.0%) 137 (0.7%)
Major bleeding 1,574 (14.0%) 1,972 (10.6%)
Non-CABG transfusion 932 (8.9%) 908 (5.3%)
Abbreviations as in Tables 1 and 2.course of critically ill patients (25–29) obese patients aremore susceptible to comorbid respiratory complications
such as aspiration pneumonia (30), pulmonary thromboem-
bolism (31), or sleep apnea and obesity hypoventilation
syndrome (31,32). In addition, there are practical difficulties
in caring for class III obese patients who are critically ill that
may affect the in-hospital outcomes reported here, such as
prolonged immobility, difficulty obtaining venous access, or
inability to perform indicated diagnostic or therapeutic
procedures because of equipment weight restrictions (33).
It is of considerable interest that the higher unadjusted
rates of adverse outcomes in the normal-BMI subgroup,
compared with the overweight or mildly obese subgroups,
disappeared after multivariate adjustment. This finding
strongly suggests that the unadjusted association of lower
mortality with overweight or mild obesity is explained by
the effect of confounders in the normal-BMI group, such as
older age, more extensive cardiac disease, or known or
undiagnosed serious medical conditions. This raises the
provocative hypothesis that the “obesity paradox” described
in many cardiovascular disease states (11–14,20,34–36) may
be explained in whole or in part by residual confounding.
Such an explanation has been widely believed to explain
excess risk among underweight individuals with cardiovas-
cular disease but has not been applied to normal-weight
individuals. In other words, being normal weight in a
contemporary population with cardiovascular disease is now
so uncommon that it may reflect the presence of unmea-
sured serious comorbid conditions. As such, “protective”
effects that have been attributed to overweight and moderate
obesity in patients with cardiovascular disease may not
actually exist and may simply reflect unmeasured confound-
ing in normal-weight individuals. Moreover, because nor-
mal BMI may reflect unmeasured comorbidities, overweight
or mild obesity likely represents the more appropriate
referent body mass in the post-MI setting.
Obesity and in-hospital major bleeding. In contrast to
the associations observed for in-hospital mortality, the risk
for major bleeding was not significantly higher in the class
III obese patients compared with the class I obese patients
BMI Category (kg/m2)
Class I Obese
(30 to <35)
Class II Obese
(35 to <40)
Class III Obese
(>40)
(n  11,234) (n  4,376) (n  2,548)
461 (4.3%) 182 (4.4%) 147 (6.1%)
103 (1.0%) 40 (1.0%) 29 (1.2%)
540 (5.0%) 211 (5.1%) 171 (7.1%)
552 (5.1%) 215 (5.2%) 152 (6.3%)
608 (5.7%) 269 (6.5%) 159 (6.6%)
71 (0.7%) 23 (0.6%) 14 (0.6%)
1,062 (9.9%) 388 (9.3%) 288 (11.9%)
471 (4.8%) 191 (5.0%) 147 (6.5%)after adjusting for patient baseline characteristics. This
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tality with obesity do not also contribute to higher bleeding
rates and that bleeding-related complications are unlikely to
explain the excess mortality in the class III obese. The lack
of an unfavorable bleeding signal in the class III obese likely
reflects the younger age and lower overall bleeding risk
profile of the more obese patients, as well as the generally
high quality of care applied to all patients, including the very
obese. Excess dosing of anticoagulant and antiplatelet drugs
likely occurs less often in more obese patients, which would
potentially mitigate bleeding risks. In contrast, it is plausible
that relative underdosing of anticoagulant and antiplatelet
medications could contribute to the excess mortality de-
scribed here, a hypothesis that merits further exploration
with pharmacokinetic and pharmacodynamic studies tar-
geted specifically at individuals with class III obesity.
Study limitations. The present study used registry data
and thus could not account for confounders that are not
captured in the database. Centers participating in the
registry may differ systematically from facilities that do not,
especially with regard to processes of care and attention to
quality-of-care metrics. Patients in the registry are mostly
white and more likely to be men, which may limit gener-
alizability to other populations, especially African American
and Hispanic women, who have substantially higher rates of
obesity and are less well represented in the present study.
Information on radial versus femoral access is not available,
so we could not assess the possible role of radial access in
lowering bleeding risks in class III obese patients. Data
reported here can only establish the association between
BMI and in-hospital outcomes; no long-term follow-up
data are available.
Conclusions
In this large, multicenter cohort of 50,149 patients with
STEMI, extreme obesity (BMI 40 kg/m2) was indepen-
ently associated with in-hospital death compared with
lass I obesity after multivariate adjustment for potential
onfounding. This is true despite the fact that extremely
bese patients present more than a decade younger, with less
xtensive coronary artery disease and better LV systolic
unction and with better renal function. In addition, pro-
esses and quality-of-care measures were generally excellent
or class III obese patients, showing no evidence of system-
tic bias adversely affecting morbidly obese patients. This
omewhat surprising finding likely reflects how ubiquitous
besity, even class III obesity, is in modern practice. The
nigma of patients who are at lower a priori risk and receive
imilar care but nevertheless have worse outcomes mandates
urther attention and elucidation as the population preva-
ence of class III obesity continues to grow at a pace that far
xceeds the overall rise in obesity.Reprint requests and correspondence: Dr. Sandeep R. Das,
University of Texas Southwestern Medical Center, 5323 Harry
Hines Boulevard, Dallas, Texas 75390-9047. E-mail: sandeep.
as@utsouthwestern.edu.
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